Chenodeoxycholic acid
( DrugBank: Chenodeoxycholic acid / KEGG DRUG: Chenodiol )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 20 | Adrenoleukodystrophy | 1 |
| 96 | Crohn disease | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 234 | Peroxisomal disease (except Adrenoleukodystrophy) | 1 |
| 263 | Cerebrotendinous xanthomatosis | 6 |
20. Adrenoleukodystrophy
Clinical trials : 68 / Drugs : 74 - (DrugBank : 32) / Drug target genes : 25 - Drug target pathways : 131
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,737 / Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
234. Peroxisomal disease (except Adrenoleukodystrophy)
Clinical trials : 115 / Drugs : 59 - (DrugBank : 20) / Drug target genes : 15 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
263. Cerebrotendinous xanthomatosis
Clinical trials : 8 / Drugs : 9 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 3
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|